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Abstract: Sublingual immunotherapy (SLIT) is now accepted as a
viable alternative to the traditional injection route based on more than 40
clinical trials and severalmeta-analyses of efficacy. In addition, the safety
profile is very favorable, also in younger children. Although some
aspects need to be further clarified (eg, optimal doses, patient selection,
and mechanisms of action), SLIT can be currently regarded as an
additional therapeutic option that allergists have available. The main
distinctive feature of SLIT is certainly its tolerability, safety, and
convenience for the patient. Nonetheless, as happens with injection
immunotherapy, it is mandatory that the prescription of SLIT is made by
a trained specialist, and that a detailed diagnosis is made before
prescribing it.




Since its empirical discovery,1 immunotherapy was given
via subcutaneous injections (SCIT). Nevertheless, other mod-
alities of administration were proposed and investigated during
the 20th century. The rationale was either of desensitizing the
target organs (nose or bronchi) or of achieving a systemic
desensitization by administering the allergen orally. The
sublingual administration was proposed at the beginning of the
1980s, and the first double-blind placebo-controlled (DBPC)
study was published in 1986.2 Of note, this happened just after
the British Committee for the Safety of Medicines had reported
several deaths certainly caused by SCIT and had raised serious
concerns about the safety and the risk-benefit ratio of the
treatment.3 An impressive number of clinical trials with
sublingual immunotherapy (SLIT) have been published in less
than 20 years, meta-analyses on the efficacy became available,
and additional data on the safety, compliance, and mechanisms
were also published. So far, SLIT is routinely used in many
European countries, and very recently, clinical trials started also
in the United States. In 1998, a panel of experts of the World
Health Organization, based on an extensive review of the
literature, concluded that SLIT is a viable alternative to SCIT,4
and this statement was then confirmed in a position paper of the
European Academy of Allergology and Clinical Immunology5
and in the Allergic Rhinitis and its Impact on Asthma (ARIA)
document6 that extended the indications of SLIT also to
children. Finally, a recent comprehensive review by the
American Academy of Allergy Asthma and Immunology,
despite a persisting skepticism on some points, acknowledged
the clinical value of SLIT.7
In Europe, SLIT is currently marketed by several
manufacturers, and the administration schedules and the amount
of allergen(s) vary depending on the producer, but the vaccines
commercialized are standardized either biologically or immu-
nologically. Recently, for many extracts, the content in
micrograms of the major allergens has become available.
Sublingual immunotherapy is usually given as soluble
tablets or drops to be kept under the tongue for 1 to 2 minutes
and then swallowed. Based on clinical results and pharmaco-
kinetic considerations, only the sublingual-swallow modality
is considered the correct one, therefore, the acronym SLIT
usually indicates the sublingual-swallow. Sublingual immu-
notherapy can be administered either preseasonally (stop at the
beginning of the season), precoseasonally (stop at the end of
the season), or continuously. Precoseasonal schedules are
commonly the choice for pollen allergy, whereas for perennial
allergens, continuous treatments are preferred. The amount of
allergen given during a course of SLIT is usually higher than in
an equivalent SCIT, therefore, the treatment has been also
termed high-dose SLIT.
CLINICAL EFFICACY
At present, there are more than 40 randomized, double-
blind, and placebo-controlled trials with SLIT (for review see
Cox et al7 and Passalacqua and Durham8). Most of the trials
have confirmed the clinical efficacy of SLIT in allergic
rhinitis caused by grasses, trees, ragweed, Parietaria, and
mites. Only a few studies with mites9,10 and grasses11 failed
to demonstrate a significant difference between active and
placebo groups. In 2 recent large trials, the magnitude of the
effect over placebo on symptoms and drug use was reported
to be, respectively, 16% and 28%,12 and 30% and 38%.13 The
largest study available so far, including more than 800
patients, a clear dose dependence of the clinical effect was
also demonstrated.12 A meta-analysis of 22 trials and 979
patients up to and including September 2002 concluded a
significant efficacy of SLIT over placebo in allergic rhinitis.14
Another meta-analysis of the treatment of allergic rhinitis
with SLIT in pediatric patients (aged 4Y18 years), involving
10 trials, showed that SLIT was effective as assessed by
reductions in symptom scores and rescue medications.15 The
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large majority of the studies was conducted in rhinitis, and in
fact, the first meta-analysis stated that there were too few
studies on the use of SLIT in allergic asthma to perform an
evaluation. A meta-analysis in asthma was recently repeated,
including 25 trials (either open or blinded) involving more
than 1000 adults and children.16 This meta-analysis demon-
strated a significant effect of SLIT for most of the considered
outcomes, including symptoms + medications, pulmonary
function, and overall improvement.
It is likely that the good safety profile of SLIT would
allow the expansion of its indications to conditions different
from respiratory allergy. There is, for instance, 1 randomized
controlled trial investigating the effects of SLIT in isolated
allergic conjunctivitis caused by mites.17 In this study, a
significant clinical efficacy was demonstrated at the second
year of therapy, and an increase in the conjunctival provocation
threshold was also seen at the first year. One recent study18
demonstrated that SLIT is clinically effective in the treatment
of immunoglobulin EYmediated food allergy to hazelnut, as
testified by the increase in the threshold oral provocation dose.
A recent randomized trial reported also a positive outcome in
children with mild-to-moderate atopic dermatitis.19
CLINICAL SAFETY
The main rationale of SLIT is of minimizing the risks for
adverse events; therefore, particular attention has been paid to
safety in the published studies. The most frequently and
commonly reported side effect is the onset of oral/sublingual
itching after taking the dose. This phenomenon was always
described as mild and self-resolving. Headache, rhinorrhea,
constipation, and urticaria were reported only sporadically, and
their incidence did not differ from the placebo groups.
Noticeably, no fatal adverse event has been reported in the
literature. The most recent review of the existing literature7
reported a total occurrence of 14 severe adverse events (mainly
asthma) in 20 years of clinical trials. So far, there are 3 reports
of anaphylaxis probably caused by SLIT.20Y22 A controlled
dose-finding study of safety23 involved 48 grass-allergic
patients outside the pollen season. They received SLIT for 28-
day periods at progressively increasing doses, up to 200 Kg
Phl p 5 allergen that is about 40 times the amount given with 1
injection. The overall incidence of side effects was 74%, all of
mild or moderate intensity. The most frequently reported
events were irritation of the throat and oral itching.
Postmarketing surveys usually provide more realistic
information on the safety in everyday clinical practice. There
are now several postmarketing surveys conducted both in
children and adults24Y27 available. Based on these large
surveys, the overall rate of side effects ranged between 3%
and 18% of patients and was invariantly less than 1 reaction per
1000 doses. More recently, it has been shown that the safety
profile in children younger than 5 years is optimal as well.25
PRACTICAL IMPLICATIONS
The literature confirms the clinical efficacy and safety of
SLIT. Thus, this modality of administration represents a new
therapeutic tool for the allergist to use in clinical practice. The
main clinical implication for physicians is of course the good
safety profile that allows the patient to self-manage the therapy
at home. In this regard, because SLIT is self-administered by
patients themselves, concerns about the compliance have been
raised. In recent years, some studies have attempted to
quantify the adherence to therapy in the case of SLIT by means
of unscheduled telephone interviews. This could be done as
the treatments were prepared as tablets or single-dose vials, so
that it was easy to count the remaining dose and to calculate
the adherence. In 1 study, with 126 adult patients receiving
SLIT in tablets, the compliance was reported greater than 90%
over 1 year.28 In another study of 442 patients, the compliance
measured at 3 and 6 months was reportedly higher than 75% in
86% of the patients.29 A similar study was conducted in a
population of 71 children,30 and the results did not substan-
tially differ from adults. In fact, compliance data were
available for all children at 3 months and for 56 children at
6 months. At 3 months, 85% of subjects had a compliance rate
greater than 75% (69% of them adhered greater than 90%). At
6 months, 84% had a compliance rate greater than 75% (66%
of them adhered greater than 90%).
Another practical implication, of interest for the allergist
is that, because of the optimal safety profile, it seems that a
slow updosing phase is not necessary. This approach, with a
steady dosage since the beginning, would result in a treatment
that is more patient-friendly and convenient to manage.
Preliminary experiences with the no-updosing confirmed the
feasibility of this administration,31 and a randomized trial
compared the safety of the traditional updosing regimen with
the no-updosing32 in 135 patients, with no difference in safety.
In fact, the most recent large randomized trials were all
performed with the no-updosing regimen, and their results in
terms of safety, in addition to efficacy, were as favorable as
those of the studies performed with the traditional route. Of
note, soluble tablets are a convenient and easy to manage
modality for giving the treatment. Tablets have the advantages
of simple usage, of avoiding possible dosing errors, and their
time of dissolution in the oral cavity can be exactly fixed. It is
likely that soluble tablets will be in the future the most suitable
way of administration.
Concerning the costs, it is true that the cumulative dose
of allergen given via sublingual route is higher than in SCIT,
and therefore the cost of the vaccine is higher as well.
Nonetheless, a gross estimate shows that the cost of the extract
is effectively balanced by the reduced need for medical and
nursing time, so that the global cost of SLIT is even less than
that of SCIT. A formal cost-benefit analysis by a pharmacoe-
conomic model33 showed that SLIT for pollinosis in patients
with rhinitis and/or asthma leads to a significant saving (in
terms of direct and indirect costs). The same was seen in the
pharmacoeconomic analyses performed in the large grass-
tablet studies.34,35
CONCLUSIONS
The treatment of respiratory allergy is based on allergen
avoidance, pharmacological treatment, and immunotherapy.
Immunotherapy is an allergen-oriented immunomodulation
that affects the immune response to allergens and whose action
develops over long periods (months). Sublingual immunother-
apy represents a significant advance because of safety and a
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good acceptance profile. Nonetheless, the self-administration
itself requires careful instruction and a detailed follow-up of
the patients. Its prescription must be made only by a specialist
after a detailed diagnosis has been established, and the
expected benefit-cost ratio has been carefully evaluated. The
clinical efficacy of SLIT in both asthma and rhinitis is now
supported by a large number of controlled trials and meta-
analyses. Nonetheless, some clinical points still need to be
developed: (a) the optimal dose of allergen is probably the
most important aspect to be defined; (b) the optimal duration
to achieve the maximum benefit and, possibly, to achieve a
long-term benefit plus a preventive effect; (c) the long-lasting
and preventive effects have been so far demonstrated in a
single trial; and (d) the mechanisms of action are overall
poorly known.
As per guidelines, SLIT is indicated in patients with
rhinitis or asthma or both, with low adherence or previous
severe adverse reactions to SCIT. Although no evidence of an
increased risk, for prudential reasons and in analogy to SCIT,
SLIT it is not recommended in patients with severe asthma. In
addition, the cost-efficacy and clinical value of SLIT in mild
intermittent rhinitis is a matter of discussion. Certainly, SLIT
should not be considered as a last-choice treatment, but a
complement to drug treatment. It is important to remember
that SLIT must not be regarded as a substitute for
subcutaneous immunotherapy, but rather as an additional
choice or therapeutic tool.
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